Loading cancer entity…
Loading cancer entity…
Clinical trials
292 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (43)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06597734 | A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Sep 11, 2026 | clinicaltrials |
| NCT04953312 | Calprotectin, a Biomarker of COVID-19 Severity (CALPRO)(CALPRO) | withdrawn | N/A | 0 | Assistance Publique - Hôpitaux de ParisOTHER | 1 |
| Mar 12, 2026 |
| clinicaltrials |
| NCT05895201 | High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of GVHD | withdrawn | Phase 1 / Phase 2 | 0 | Indiana UniversityOTHER | 1 | Apr 29, 2024 | clinicaltrials |
| NCT06085638 | Phase I/II Study of SY-1425 (Tamibarotene) in Combination With Azacitidine and Venetoclax for Patients With Chronic Myelomonocytic Leukemia | withdrawn | Phase 1 / Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Mar 7, 2024 | clinicaltrials |
| NCT05456269 | A Study of Bisantrene Combined With Cytarabine or With Decitabine for Adult Subjects With Extramedullary AML and MDS(BISECT) | withdrawn | Phase 1 | 0 | Racura Oncology LtdINDUSTRY | 1 | Oct 3, 2023 | clinicaltrials |
| NCT05246384 | Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RP7214 in Combination With Azacitidine in Patients With Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia | withdrawn | Phase 1 / Phase 2 | 0 | Rhizen Pharmaceuticals SAINDUSTRY | 0 | Oct 31, 2022 | clinicaltrials |
| NCT04217720 | SNS-301 Monotherapy in High Risk MDS and CMML | withdrawn | Phase 2 | 0 | Sensei Biotherapeutics, Inc.INDUSTRY | 0 | Aug 12, 2021 | clinicaltrials |
| NCT03602898 | Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation | withdrawn | Phase 2 | 0 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 30, 2021 | clinicaltrials |
| NCT03807063 | Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant | withdrawn | Phase 1 | 0 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 14, 2020 | clinicaltrials |
| NCT02564536 | Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS) | withdrawn | Phase 1 | 0 | Washington University School of MedicineOTHER | 0 | May 8, 2017 | clinicaltrials |
| NCT01558778 | Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant | withdrawn | N/A | 0 | Roswell Park Cancer InstituteOTHER | 0 | Jul 9, 2012 | clinicaltrials |
Data updated 19 days agoSource updated Sep 11, 2026source: clinicaltrials